|
|
Essential drugs of hypertension and diabetes and its drug analysis based on hierarchical medical system in China |
LIU Shiyong1,2 ZHAI Yi1 WU Jing1 LIANG Xiaofeng3 |
1.Division of Non-Communicable Disease Control and Community Health, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 2.The Hospital of Central University of Finance and Economics, Beijing 100081, China;
3.Chinese Center for Disease Control and Prevention, Beijing 102206, China |
|
|
Abstract This paper checks essential medicine list and supplementary of hypertension and diabetes in some provinces, analyzes supplementary drugs coincidence rate as well as its equipment and use of hypertension and diabetes bases on hierarchical medical system in China, and finds that there is big difference in supplemented quantity of essential medicines in hypertension and diabetes, which top five of coincidence rate reaches 44.8% and 34.5%. The frequency of drug use and sales have supplemented in common compared with high coincidence rate of drugs in supplementary drugs. The paper suggests to integrate local supplement and national essential medicine list and then to increase drugs with effective treatment, less adverse reaction, high independence of patients and relatively low average daily expenses, and adjust high frequency or supplemented high coincidence rate of drugs to the next version of national essential medicine list, so as to narrow the difference of essential medicines list between the grassroots medical institutions and general hospitals, and promote the priority of essential drugs.
|
|
|
|
|
[1] 覃正碧,汪志宏,程刚,等.国家基本药物制度的现状及其完善对策探讨[J].中国药房,2008,19(14):1041-1044.
[2] 杨悦,李姗,武志昂.世界卫生组织基本药物遴选原则的进展研究[J].中国药房,2011,22(28):2593-2597.
[3] 陈晶,聂青,刘妍.《WHO基本药物示范目录》与我国《国家基本药物目录》动态调整程序比较与借鉴[J].中国药房,2015,26(3):289-293.
[4] 杨皓斌,王乐三.我国基本药物制度的建立与实践[J].实用预防医学,2014,21(11):1405-1408.
[5] 常星,代涛,唐圣春.16个省级基本药物增补目录的分析研究[J].中国卫生经济,2011,30(10):53-56.
[6] 李跃平,林莉,黄子杰,等.我国各地基本药物增补情况分析[J].药学服务与研究,2012,12(2):90-93.
[7] 杨志云.2013年全国卫生工作会议在京召开 全面贯彻落实党的十八大精神 为提高人民健康水平而努力奋斗[J].中医药管理杂志,2013(1):F0004.
[8] 商金鑫,郭志刚,林其敏,等.北京市基本药物可及性评价研究[J].中国卫生政策研究,2016,9(2):52-58.
[9] Yu F,Wagner AK,Yang S,et al. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province,western China [J]. Lancet Global Health,2013,1(4):e227.
[10] 裴晔,何宁.北京市某医院抗高血压类基本药物使用情况分析[J].卫生经济研究,2015(3):55-58.
[11] 李晓玲,王育琴,王香平,等.六省区18家二级医院基本药物使用情况调研[J].中国药房,2012,23(48):4523-4527.
[12] 贾德文.2013-2014年我院抗高血压药物临床使用情况分析[C].中国转化医学和整合医学研讨会,2015.
[13] 杜继东.2012-2014年天津市河北区铁东路街社区卫生服务中心抗高血压药的使用情况分析[J].现代药物与临床,2015,30(7):875-879.
[14] 杨赞.2010年-2014年我院抗高血压药物的应用特点分析[J].大家健康:学术版,2015(11):140-141.
[15] 王思思,林鸿波,沈鹏,等.宁波市某区424家基层医疗卫生机构2010-2013年抗高血压药使用趋势分析[J].中国药房,2014,25(38):3559-3561.
[16] 俞颖,张会杰.我院2012-2014年口服降糖药临床应用分析[J].湖北民族学院学报:医学版,2015,32(4):60-63.
[17] 丁晶,刘东.武汉地区34家医院2011-2013年口服降糖药应用分析[J].中国药房,2015,26(26):3635-3639.
[18] 金燕,叶桦.我院使用国家基本药物与增补目录中抗高血压药品的现状分析[J].中国药事,2012,26(3):258-260.
[19] 杨洁心,杨世民.我国29省基本药物增补目录对比分析[J].中国执业药师,2013,10(4):9-16.
[20] 高悦,蔡雯.29省基本药物增补目录比对分析[J].中国实验方剂学杂志,2012,18(21):351-353.
[21] 张皓,王林浩,余海,等.基本药物制度对基层医疗机构服务能力和分级诊疗的影响[J].中华医院管理杂志,2015, 31(12):928-930. |
|
|
|